LeMaitre Vascular is a provider of medical devices and human tissue cryopreservation services for the treatment of peripheral vascular disease, end-stage renal disease, and to a lesser extent cardiovascular disease. Co. develops, manufactures, and markets vascular devices to address the needs of vascular surgeons. Co.'s portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart and includes the LeMaitre valvulotome, the XenoSure biologic patch, the Artegraft collagen vascular graft, the Pruitt F3 carotid shunt, VascuTape radiopaque tape, and Syntel embolectomy catheters. The LMAT stock yearly return is shown above.
The yearly return on the LMAT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LMAT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|